Lanifibranor

DB14801InvestigationalSmall molecule

Lanifibranor is under investigation in clinical trial NCT03008070 (Phase 2b Study in NASH to Assess IVA337).

Chemical structure of Lanifibranor
Mechanism
Curator reviewed
Formula / weight
C19H15ClN2O4S2 · 434.91 g/mol (avg)
Code names
IVA 337

Resolves to

Compound
UNII28Q8AG0PYLCAS927961-18-0ChEMBLCHEMBL4091374
Structure
InChIKeyOQDQIFQRNZIEEJ-UHFFFAOYSA-NSMILESOC(=O)CCCC1=CC2=C(C=CC(Cl)=C2)N1S(=O)(=O)C1=CC2=C(C=C1)N=CS2
Targets
P37231PPARGQ03181PPARDQ07869PPARA

What you can answer from here — as of June 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Lanifibranor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In